Philips Virtual Care Management offers a comprehensive approach to telehealth for patients, providers and payers
March 27, 2023
New solution demonstrates proven results in improving patient engagement, health outcomes, and lowering cost of care while enabling workflow efficiencies
Amsterdam, the Netherlands –Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the debut of Philips Virtual Care Management, a comprehensive portfolio of flexible solutions and services to help health systems, providers, payers and employer groups more meaningfully motivate and deeply connect with patients from virtually anywhere. Philips Virtual Care Management can help reduce pressure on hospital staff by decreasing emergency department visits, as well as reducing the cost of care through better management of chronic disease .
Every year, chronic condition management represents 90% of healthcare expenditures in the USA . Philips Virtual Care Management’s condition-specific protocols now include diabetes, hypertension, heart disease, chronic kidney disease, chronic obstructive pulmonary disease (COPD), as well as gestational programs for diabetes and hypertension. These protocols combine with connected devices and engagement tools on a secure, interoperable cloud-based platform to deliver rich data and actionable insights that enable timely intervention and workflow efficiencies. Licensed clinical professionals offer monitoring and personalized health coaching; and Philips’ expert-led professional services round out the all-inclusive offering to help customers plan, customize, implement, activate and sustain each program.
“Virtual care is paving the way to meaningfully reduce the cost of care through fewer hospitalizations and emergency department visits,” said Nick Wilson, General Manager, Ambulatory Virtual Care at Philips. “Care providers and health systems today are often short on time and resources, accelerating the need to find new ways to gain visibility into patients’ health amid an overwhelming variety of options. For patients, the opportunity to understand and take proactive control of their health can potentially lead to improved outcomes.”
Philips’ advanced virtual care program goes beyond traditional remote patient management with scalable solutions and services that help to foster strong patient engagement, empower healthier behaviors, expand access to care, improve outcomes, and lower healthcare costs. Recent studies using Philips Virtual Care Management products and services demonstrated impressive results:
- Patients saw a 38% average reduction in emergency department visits 
- Patients experienced an average HbA1c, or blood glucose, reduction of 3.06% 
- Results suggest potential savings of USD 3,086 annual claims per patient or member 
- Results suggest fewer 30- and 90-day hospitalizations compared to usual care 
A comprehensive program with a flexible fit
The highly configurable Philips Virtual Care Management solution offers health systems, providers, payers and employer groups the unique ability to customize their program in a way that shapes and scales with their evolving needs. Philips’ legacy of clinical expertise brings a clearly defined, comprehensive approach to an otherwise fragmented virtual care market by working alongside customers to help them centralize and customize their Philips Virtual Care Management program, optimize workflow and improve outcomes.
On Tuesday, March 28 at 12:00 CT, Nick Wilson will showcase Philips Virtual Care Management on the Tech Talks stage at ViVE 2023 in Nashville during a brief session entitled “Unlock the power of human-centered care, virtually anywhere.” To learn more about Philips’ extensive portfolio of ambulatory virtual care solutions, visit Philips booth #1404 at ViVE or philips.com/virtualcaremanagement.
Philips Virtual Care Management is not currently available outside the USA.
 Magee MF, Baker KM, Fernandez SJ, et al. Redesigning ambulatory care management for uncontrolled type 2 diabetes: a prospective cohort study of the impact of a Boot Camp model on outcomes. BMJ Open Diabetes Res Care. 2019;7(1):e000731. Published 2019 Nov 13. doi:10.1136/bmjdrc-2019-000731.
 A Diabetes Care Management Program for uncontrolled type 2 diabetes in a predominantly African American population amortized over the study cohort due to reduced risk of all factors hospitalization after 90 days compared to usual care.
 Remote patient monitoring system market size, share and trends analysis report by product (vital sign monitors, specialized monitors), by end use, by application, and segment forecasts, 2022-2030. Grand View Research. Accessed November 16, 2022. https://www.grandviewresearch.com/industry-analysis/remote-patient-monitoring-devices-market.
 Following a 90-day diabetes care management program in 366 subjects with type 2 diabetes, average baseline HbA1c: 11.2%.
 30 day incidence risk ratio = Intervention (0.21, 95%CI 0.07 to 0.60; p=0.003) vs control (1.14, 95%CI 0.47 to 2.75; p=0.77); between group (p=0.02). 90 day IIR = intervention (0.23, 95%CI 0.11 to 0.50, p<0.001) vs. control (1.58, 95%CI 0.750 to 3.33; p=0.23); between group (P<0.001).
For further information, please contact:
Philips Global Press Office
Tel.: +1 724 584 8991
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
AttachmentsTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Sai Life Sciences reaffirms commitment to Sustainability, charts out SDGs to be achieved by FY276.6.2023 12:41:52 CEST | Press release
HYDERABAD, India, June 06, 2023 (GLOBE NEWSWIRE) -- On the World Environment Day 2023, Sai Life Sciences, a global Contract Research, Development & Manufacturing Organization (CRO-CDMO), announced its renewed Sustainable Development Goals (SDG) charting out the roadmap to achieve specific environmental, social and governance (ESG) targets by the financial year ending March 31, 2027. Making the announcement, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said, “Our renewed Sustainable Development Goals reflect a coming of age of our Sustainability journey. The learnings and successes from the first edition have shaped our aspiration for this phase and signify a certain boldness that comes with persevering unabated on a chosen path. While Sustainability has always been at the heart of our ethos at Sai Life Sciences, I must thank all our customers and partners for inspiring us raise the bar each day.” Sai Life Sciences first charted out its SDGs in 2019 with a three-year ti
Calibre Announces the Publication of its 2022 Sustainability Report, Demonstrating Commitment to Transparency and Responsible Practices6.6.2023 12:00:55 CEST | Press release
VANCOUVER, British Columbia, June 06, 2023 (GLOBE NEWSWIRE) -- Calibre Mining Corp. (TSX: CXB; OTCQX: CXBMF) (“Calibre” or the “Company”) is pleased to announce the publication of its 2022 Sustainability Report (“the Report”). The Report outlines Calibre’s 2022 progress and achievements, provides guidance for the Company’s Environmental, Social and Governance (“ESG”) performance, and underscores Calibre’s unwavering commitment to transparency, accountability and responsible business practices. Calibre acknowledges that incorporating sustainability into its business strategy is essential to our long-term success. In 2022, the Company saw record production for the third consecutive year. Calibre’s increasing focus on sustainability practices and robust ESG performance ensures that such accomplishments are achieved in ways that are ethical, transparent, accountable, and respectful of the rights of others. Darren Hall, President and Chief Executive Officer, stated: “At Calibre, we recogniz
Noted Vaccine Researcher Thomas P. Monath Awarded Sabin’s Gold Medal; Cameroon Physician Sangwe Clovis Nchinjoh Receives Rising Star Award6.6.2023 12:00:00 CEST | Press release
WASHINGTON, June 06, 2023 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute today awarded the 30th Albert B. Sabin Gold Medal Award to Thomas P. Monath, MD, and its Rising Star Award to Sangwe Clovis Nchinjoh, MD, MPH, in a ceremony at Washington D.C.’s National Academy of Sciences building. Dr. Monath was selected for the Gold Medal for his more than four decades of commitment to advancing knowledge of arboviruses and vaccine research and development (R&D) that contributed to the development of several innovative vaccines including those for Ebola Zaire, smallpox, dengue, Japanese encephalitis and West Nile. The Gold Medal, celebrating three decades of recognition, is Sabin’s highest scientific honor. It is given annually to a distinguished member of the global health community who has made exceptional contributions to vaccinology or a complementary field. Past award recipients include leaders of vaccinology and vaccine advocacy such as Drs. Barney Graham, Carol Baker, Bill Foege, Anne
PRESS RELEASE: SSH launches OpenSSH support service for multi-platform SSH environments6.6.2023 12:00:00 CEST | Press release
Helsinki, Finland - June 6, 2023 - To resolve various customer support problems regarding OpenSSH implementations, SSH has launched a support service for OpenSSH. As a result, customers benefit from high-quality SSH support services also for the open-source variant of SSH software. OpenSSH will be supported on Windows and Red Hat Linux platforms. The SSH protocol is a secure network protocol used to establish encrypted and secure remote connections and transfer data between different systems. OpenSSH is an open-source implementation of the SSH protocol. It was initially released as a free version of SSH’s Tectia product. As an open-source product, OpenSSH is popular, especially as SSH client software. However, its usage in critical corporate environments has been partly limited due to a lack of high-quality support services or support from a single source for all SSH clients. Without proper support services, customers often invest in in-house OpenSSH expertise, resulting in increased o
Novo Nordisk A/S – Share repurchase programme6.6.2023 11:56:26 CEST | Press release
Bagsværd, Denmark, 6June 2023 – On 9 May 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023. Under the programme initiated 9 May 2023, Novo Nordisk will repurchase B shares for an amount up to DKK 5.8 billion in the period from 10 May 2023 to 8 August 2023. Since the announcement 30 May of the programme, the following transactions have been made: Number of B sharesAverage purchase priceTransaction value, DKKAccumulated, last announcement906,0001,042,810,01330 May 202382,7001,123.3192,897,99931 May 202385,0001,117.9295,023,0001 June 202385,0001,109.7994,332,2702 June 202390,0001,076.5596,889,206Accumulated under the